Loss of Heterozygosity at the Thymidylate Synthase (TS) Locus on Chromosome 18 Affects Tumor Response and Survival in Individuals Heterozygous for A 28-bp Polymorphism in the TS Gene

Clinical Cancer Research

Volumn 10, Issue 2, 2004, Pages 433-439

  Uchida, Kazumi ^a,b   Hayashi, Kazuhiko ^b   Kawakami, Kazuyuki ^a   Schneider, Sylke ^a   Yochim, Ji Min ^a   Kuramochi, Hidekazu ^b   Takasaki, Ken ^b   Danenberg, Kathleen D ^c   Danenberg, Peter V ^a,d  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^b TOKYO WOMEN'S MEDICAL UNIVERSITY   (Japan)

^c Response Genetics Inc   (United States)

^d UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

5 CHLORO 2,4 DIHYDROXYPYRIDINE PLUS OXONATE POTASSIUM PLUS TEGAFUR; DNA; FLUOROPYRIMIDINE DERIVATIVE; THYMIDYLATE SYNTHASE;

ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER SURVIVAL; CHROMOSOME 18; CLINICAL ARTICLE; CLINICAL TRIAL; COLORECTAL CANCER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG RESPONSE; FEMALE; GENE; GENE LOCUS; GENETIC POLYMORPHISM; GENOTYPE; HETEROZYGOSITY; HETEROZYGOSITY LOSS; HUMAN; HUMAN TISSUE; MALE; PRIORITY JOURNAL; PROMOTER REGION; TANDEM REPEAT; TS GENE;

ADULT; AGED; ANTIMETABOLITES, ANTINEOPLASTIC; CHROMOSOMES, HUMAN, PAIR 18; COLORECTAL NEOPLASMS; DNA; DNA, COMPLEMENTARY; DRUG COMBINATIONS; ELECTROPHORESIS; FEMALE; GENOTYPE; HETEROZYGOTE; HOMOZYGOTE; HUMANS; LOSS OF HETEROZYGOSITY; MALE; MIDDLE AGED; OXONIC ACID; POLYMERASE CHAIN REACTION; POLYMORPHISM, GENETIC; PYRIDINES; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA; TEGAFUR; THYMIDYLATE SYNTHASE; TIME FACTORS; TREATMENT OUTCOME;

EID: 0842268401     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-0200-03     Document Type: Article

References (34)

1. Danenberg, P. V. Thymidylate synthetase - a target enzyme in cancer chemotherapy. Biochim. Biophys. Acta, 473: 73-92, 1977.
2. Wang, W., Marsh, S., Cassidy, J., and McLeod, H. L. Pharmacogenomic dissection of resistance to thymidylate synthase inhibitors. Cancer Res., 61: 5505-5510, 2001.
3. Huang, C. L., Yokomise, H., Kobayashi, S., Fukushima, M., Hitomi, S., and Wada, H. Intratumoral expression of thymidylate synthase and dihydropyrimidine dehydrogenase in non-small cell lung cancer patients treated with 5-FU-based chemotherapy. Int. J. Oncol., 17: 47-54, 2000.
4. Nishimura, R., Nagao, K., Miyayama, H., Matsuda, M., Baba, K., Matsuoka, Y., Yamamashita, H., Fukuda, M., Higuchi, A., Satoh, A., Mizumoto, T., and Hamamoto R., Thymidylate synthase levels as a therapeutic and prognostic predictor in breast cancer. Anticancer Res., 19: 5621-5626, 1999.
5. Salonga, D., Danenberg, K. D., Johnson, M., Metzger, R., Groshen, S., Tsao-Wei, D. D., Lenz, H. J., Leichman, C. G., Diasio, R. B., and Danenberg, P. V. Colorectal tumors responding to 5-fluorouracil have low gene expression levels of dihydropyrimidine dehydrogenase, thymidylate synthase, and thymidine phosphorylase. Clin. Cancer Res., 6: 1322-1327, 2000.
6. Shirota, Y., Stoehlmacher, J., Brabender, J., Xiong, Y. P., Uetake, H., Danenberg, K. D., Groshen, S., Tsao-Wei, D. D., Danenberg, P. V., and Lenz, H. J. ERCC1 and thymidylate synthase mRNA levels predict survival for colorectal cancer patients receiving combination oxaliplatin and fluorouracil chemotherapy. J. Clin. Oncol., 19: 4298-4304, 2001.
7. Yeh, K. H., Shun, C. T., Chen, C. L., Lin, J. T., Lee, W. J., Lee, P. H., Chen, Y. C., and Cheng, A. L. High expression of thymidylate synthase is associated with the drug resistance of gastric carcinoma to high dose 5-fluorouracil-based systemic chemotherapy. Cancer (Phila.), 82: 1626-1631, 1998.
8. Kralovanszky, J., Koves, I., Orosz, Z., Katona, C., Toth, K., Rahoty, P., Czegledi, F., Kovacs, T., Budai, B., Hullan, L., and Jeney, A. Prognostic significance of the thymidylate biosynthetic enzyme in human colorectal tumors. Oncology, 62: 167-174, 2002.
9. Nakagawa, T., Tanaka, F., Otake, Y., Yanagihara, K., Miyahara, R., Matuoka, K., Takata, T., Yamada, T., Fukushima, M., and Wada, H. Prognostic value of thymidylate synthase expression in patients with p-stage I adenocarcinoma of the lung. Lung Cancer, 35: 165-170, 2002.
10. Kaneda, S., Takeishi, K., Ayusawa, D., Shimizu, K., Seno, T., and Altman, S. Role in translation of a triple tandemly repeated sequence in the 5′-untranslated region of human thymidylate synthase mRNA. Nucleic Acids Res., 15: 1259-1270, 1987.
11. Marsh, S., Collie-Duguid, E. S., Li, T., Liu, X., and McLeod, H. L. Ethnic variation in the thymidylate synthase enhancer region polymorphism among Caucasion and Asian populations. Genomics, 58: 310-312, 1999.
12. Horie, N., Aiba, H., Oguro, K., Hojo, H., and Takeishi, K. Functional analysis and DNA polymorphism of the tandemly repeated sequences in the 5′-terminal regulatory region of the human gene for thymidylate synthase. Cell Struct. Funct., 20: 191-197, 1995.
13. Kawakami, K., Omura, K., Kanehira, E., and Watanabe, Y. Polymorphic tandem repeats in the thymidylate synthase gene is associated with its protein expression in human gastrointestinal cancers. Anticancer Res., 19: 3249-3252, 1999.
14. Kawakami, K., Salonga, D., Park, J. M., Danenberg, K. D., Uetake, H., Brabender, J., Omura, K., Watanabe, G., and Danenberg, P. V. Different lengths of polymorphic repeat sequence in the thymidylate synthase gene affect translational efficiency but not its gene expression. Clin. Cancer Res., 7: 4096-4101, 2001.
15. Iacopetta, B., Grieu, F., Joseph, D., and Elsaleh, H. A polymorphism in the enhancer region of the thymidylate synthase promoter influences the survival of colorectal cancer patients treated with 5-fluorouracil. Br. J. Cancer, 85: 827-830, 2001.
16. Marsh, S., McKay, J. A., Cassidy, J., and McLeod, H. L. Polymorphism in the thymidylate synthase promoter enhancer region in colorectal cancer. Int. J. Oncol., 19: 383-386, 2001.
17. Pullarkat, S. T., Stoehlmacher, J., Ghaderi, V., Xiong, Y. P., Ingles, S. A., Sherrod, A., Warren, R., Tsao-Wei, D., Groshen, S., and Lenz, H. J. Thymidylate synthase gene polymorphism determines response and toxicity of 5-FU chemotherapy. Pharmacogenomics J., 1: 65-70, 2001.
18. Villafranca, E., Okruzhnov, Y., Dominguez, M. A., Garcia-Foncillas, J., Azinovic, I., Martinez, E., Illarramendi, J. J., Arias, F., Martinez Monge, R., Salgado, E., Angeletti, S., and Brugarolas, A. Polymorphisms of the repeated sequences in the enhancer region of the thymidylate synthase gene promoter may predict downstaging after preoperative chemoradiation in rectal cancer. J. Clin. Oncol., 19: 1779-1786, 2001.
19. Zinzindohoue, F., Ferraz, J-M., and Laurent-Puig, P. Thymidylate synthase promoter polymorphism. J. Clin. Oncol., 19: 3442, 2001.
20. Kawakami, K., Ishida, Y., Danenberg, K. D., Omura, K., Watanabe, G., and Danenberg, P. V. Functional polymorphism of the thymidylate synthase gene in colorectal cancer accompanied by frequent loss of heterozygosity. Jpn. J. Cancer Res., 93: 1221-1228, 2002.
21. Sakata, Y., Ohtsu, A., Horikoshi, N., Sugimachi, K., Mitachi, Y., and Taguchi, T. Late phase II study of novel oral fluoropyrimidine anticancer drug S-1(1 M tegafur-0.4 M gimestat-1 M otastat potassium) in advanced gastric cancer patients. Eur. J. Cancer, 34: 1715-1720, 1998.
22. Koizumi, W., Kurihara, M., Nakano, S., and Hasegawa, K. Phase II study of S-1, a novel oral derivative of 5-fluorouracil, in advanced gastric cancer. Oncology, 58: 191-197, 2000.
23. Green, S., and Weiss, G. R. Southwest Oncology Group standard response criteria, endpoint definitions, and toxicity criteria. Investig. New Drugs, 10: 239-253, 1992.
24. Lord, R. V., Salonga, D., Danenberg, K. D., Peters, J. H., DeMeester, T. R., Park, J. M., Johansson, J., Skinner, K. A., Chandrasoma, P., DeMeester, S. R., Bremner, C. G., Tsai, P. I., and Danenberg, P. V. Telomerase reverse transcriptase expression is increased early in the Barrett's metaplasia, dysplasia, adenocarcinoma sequence. J. Gastrointest. Surg., 4: 135-142, 2000.
25. Heid, C. A., Stevens, J., Livak, K. J., and Williams, P. M. Real time quantitative PCR. Genome Res., 6: 986-994, 1996.
26. Gibson, U. E., Heid, C. A., and Williams, P. M. A novel method for real time quantitative RT-PCR. Genome Res., 6: 995-1001, 1996.
27. Hori, T., Takahashi, E., Ayusawa, D., Takeishi, K., Kaneda, S., and Seno, T. Regional assignment of the human thymidylate synthase (TS) gene to chromosome band 18p11.32 by nonisotopic in situ hybridization. Human Genetics, 85: 576-580, 1990.
28. Vogelstein, B., Fearon, E. R., Kern, S. E., Hamilton, S. R., Preisinger, A. C., Nakamura, Y., and White, R. Allelotype of colorectal carcinomas. Science (Wash. DC), 244: 207-211, 1989.
29. Etienne, M. C., Chazal, M., Laurent-Puig, P., Magne, N., Rosty, C., Formento, J. L., Francoual, M., Formento, P., Renee, N., Chamorey, E., Bourgeon, A., Seitz, J. F., Delpero, J. R., Letoublon, C., Pezet, D., and Milano, G. Prognostic value of tumoral thymidylate synthase and p53 in metastatic colorectal cancer patients receiving fluorouracil-based chemotherapy: phenotypic and genotypic analyses. J. Clin. Oncol., 20: 2832-2843, 2002.
30. Trinh, B. N., Ong, C-N., Coetzee, G. A., Yu, M. C., and Laird, P. W. Thymidylate synthase: a novel genetic determinant of plasma homocysteine and folate levels. Hum. Genet., 111: 299-302, 2002.
31. Niyikiza, C., Baker, S. D., Seitz, D. E., Walling, J. M., Nelson, K., Rusthoven, J. J., Stabler, S. P., Paoletti, P., Calvert, A. H., and Allen, R. H. Homocysteine and methylmalonic acid: markers to predict and avoid toxicity from pemetrexed therapy. Mol. Cancer Ther., 1: 545-552, 2002.
32. Krajinovic, M., Costea, I., and Ciasson, S. Polymorphism of the thymidylate synthase gene and outcome of acute lymphoblastic leukaemia. Lancet, 359: 1033-1034, 2002.
33. Ulrich, C. M., Bigler, J., Bostick, R., Fosdick, L., and Potter, J. D. Thymidylate synthase promoter polymorphism, interaction with folate intake, and risk of colorectal carcinomas. Cancer Res., 62: 3361-3364, 2002.
34. Skibola, C. F., Smith, M. T., Hubbard, A., Shane, B., Roberts, A. C., Law, G. R., Rollinson, S., Roman, E., Cartwright, R. A., and Morgan, G. J. Polymorphisms in the thymidylate synthase and serine hydroxymethyltransferase genes and risk of adult acute lymphocytic leukemia. Blood, 99: 3786-3791, 2002.